Gianvito Masi, MD
Associate Research ScientistCards
About
Research
Publications
2025
IgA autoantibodies demonstrate a novel mechanism of MuSK myasthenia gravis pathology
Masi G, Chen K, Bayer A, Bayarri-Olmos R, Pham M, Wallace A, Falso S, Evoli A, Iorio R, Hoehn K, Iwasaki A, Nowak R, O'Connor K. IgA autoantibodies demonstrate a novel mechanism of MuSK myasthenia gravis pathology. Brain 2025, awaf410. PMID: 41147199, DOI: 10.1093/brain/awaf410.Peer-Reviewed Original ResearchMuSK-MGIgA AbsIgA B cellsIgA mAbB cellsMyasthenia gravisIgG AbsTherapeutic B cell depletionMuscle-specific tyrosine kinaseB-cell depletionB cell receptor sequencesPathogenic effectsPolyclonal IgA responsesProgressive weight lossMuSK-AbIgA seropositivityMucosal sitesPolyclonal responseAutoimmune conditionsPassive immunization experimentsIgA autoantibodiesIgA responsesAb isotypesDiscovery cohortIndependent cohortTherapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathology
Bayer A, Sanmarco L, Pellerin A, Masi G, Plasencia A, Anderson J, Nowak R, Damato V, Massacesi L, Pham M, Khani-Habibabadi F, Vital H, Higginson-Scott N, Otipoby K, Xing Y, Mascanfroni I, O’Connor K. Therapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathology. Proceedings Of The National Academy Of Sciences Of The United States Of America 2025, 122: e2505984122. PMID: 41118207, PMCID: PMC12582293, DOI: 10.1073/pnas.2505984122.Peer-Reviewed Original ResearchConceptsMyasthenia gravisComplement depositionLive cell-based assayComplement activationTherapeutic potentialAcetylcholine receptor autoantibodiesPathogenic effectsReceptor autoantibodiesAChR autoantibodiesAutoantibody-mediated pathologyAutoimmune disordersPatient cohortIgG autoantibodiesEffector functionsPatient stratificationMuscle weaknessPersonalized therapySerum IgGAutoantibodiesPatientsReceptor bindingAcetylcholine receptorsIgGSerum samplesCell-based assaysScreening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing.
Krenn M, Wagner M, Schuller H, Pugna I, Rath J, Zulehner G, Keritam O, Weng R, Koneczny I, Schiavo E, Damato V, Kleinveld V, Kiss C, Gold V, Quasthoff S, Masi G, O'Connor K, Canning J, Waters P, Lenz D, Blüthner M, Pavlov M, Graf E, Winkelmann J, Löscher W, Zimprich F, Cetin H. Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing. Neurology 2025, 105: e214177. PMID: 41004697, DOI: 10.1212/wnl.0000000000214177.Peer-Reviewed Original ResearchConceptsCongenital myasthenic syndromeWhole-exome sequencingSeronegative MGMyasthenic syndromeMyasthenia gravisDisease onsetMolecular diagnosisVoltage-gated calcium channelsSeronegative myasthenia gravisTertiary neuromuscular centersResponse to immunotherapyLipoprotein receptor-related protein 4Associated with autoantibodiesProportion of patientsComprehensive serological testingPositive family historyMuscle-specific kinaseDemographic factorsReceiving immunotherapyPartial responseSeronegative patientsMedian ageImmunomodulatory treatmentCalcium channelsAdult patientsMolecular and Functional Characterization of Self-Reactive IgA Autoantibodies in Patients with Muscle-specific Tyrosine Kinase Myasthenia Gravis (S34.007)
Masi G, Chen K, Pham M, Wallace A, Nowak R, O’Connor K. Molecular and Functional Characterization of Self-Reactive IgA Autoantibodies in Patients with Muscle-specific Tyrosine Kinase Myasthenia Gravis (S34.007). Neurology 2025, 104 DOI: 10.1212/wnl.0000000000209092.Peer-Reviewed Original Research
2024
Unveiling the proteome-wide autoreactome enables enhanced evaluation of emerging CAR-T therapies in autoimmunity
Bodansky A, Yu D, Rallistan A, Kalaycioglu M, Boonyaratanakornkit J, Green D, Gauthier J, Turtle C, Zorn K, O'Donovan B, Mandel-Brehm C, Asaki J, Kortbawi H, Kung A, Rackaityte E, Wang C, Saxena A, de Dios K, Masi G, Nowak R, O'Connor K, Li H, Diaz V, Saloner R, Casaletto K, Gontrum E, Chan B, Kramer J, Wilson M, Utz P, Hill J, Jackson S, Anderson M, DeRisi J. Unveiling the proteome-wide autoreactome enables enhanced evaluation of emerging CAR-T therapies in autoimmunity. Journal Of Clinical Investigation 2024, 134: e180012. PMID: 38753445, PMCID: PMC11213466, DOI: 10.1172/jci180012.Peer-Reviewed Original ResearchB-cell maturation antigenImmunomodulatory therapyPlasma cell-targeted therapyCAR-T therapyCell-targeted therapyAutoantibody mediated diseasesCAR-TAnti-CD19Maturation antigenAutoantibody profileAutoreactive antibodiesTargeted therapyPlasma cellsAutoimmune diseasesAutoantibody repertoireTherapyMediated diseasesAutoantibodiesTherapeutic interventionsProteome-wideDisease statesDiseaseImmunological fingerprintPhIP-SeqMinimal effect
2023
Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology
Pham M, Masi G, Patzina R, Obaid A, Oxendine S, Oh S, Payne A, Nowak R, O’Connor K. Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology. Acta Neuropathologica 2023, 146: 319-336. PMID: 37344701, PMCID: PMC11380498, DOI: 10.1007/s00401-023-02603-y.Peer-Reviewed Original ResearchConceptsMyasthenia gravisAntigenic modulationPathogenic mechanismsAutoimmune myasthenia gravisCurrent therapeutic approachesΑ-bungarotoxin bindingNicotinic acetylcholine receptorsReceptor blockadeSerum autoantibodiesAutoreactive clonesMonoclonal levelTherapeutic approachesMonoclonal autoantibodiesAcetylcholine receptorsComplement activationAutoantibodiesAChR subunitsJurkat cell lineDistinct molecular mechanismsPathogenic profilePathogenic capacityPathologyCell-based assaysMAbsPatientsUnearthing the Rosetta Stone of public antibody responses.
Masi G. Unearthing the Rosetta Stone of public antibody responses. Science Immunology 2023, 8: eadi4342. PMID: 37146131, DOI: 10.1126/sciimmunol.adi4342.Peer-Reviewed Original ResearchClinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis
Masi G, Pham M, Karatz T, Oh S, Payne A, Nowak R, Howard J, Guptill J, Juel V, O'Connor K. Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis. Annals Of Clinical And Translational Neurology 2023, 10: 825-831. PMID: 36924454, PMCID: PMC10187728, DOI: 10.1002/acn3.51761.Peer-Reviewed Original Research
2022
Novel pathophysiological insights in autoimmune myasthenia gravis
Masi G, O’Connor K. Novel pathophysiological insights in autoimmune myasthenia gravis. Current Opinion In Neurology 2022, 35: 586-596. PMID: 35942663, PMCID: PMC9458626, DOI: 10.1097/wco.0000000000001088.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAutoimmune myasthenia gravisMyasthenia gravisMG patientsClinical responseMuscle-specific tyrosine kinaseSpecific therapeutic strategiesNovel pathophysiological insightsMG pathologyMG subtypesAutoantibody repertoireTreatment optionsCancer immunotherapyPredictive biomarkersSuch therapyImmunological heterogeneityPathophysiological insightsMG phenotypeTherapeutic strategiesClinical observationsTherapeutic outcomesAcetylcholine receptorsDisease subtypesTherapeutic perspectivesSubtypesDevelopment of assaysThe clinical need for clustered AChR cell-based assay testing of seronegative MG
Masi G, Li Y, Karatz T, Pham MC, Oxendine SR, Nowak RJ, Guptill JT, O'Connor KC. The clinical need for clustered AChR cell-based assay testing of seronegative MG. Journal Of Neuroimmunology 2022, 367: 577850. PMID: 35366559, PMCID: PMC9106915, DOI: 10.1016/j.jneuroim.2022.577850.Peer-Reviewed Original ResearchConceptsSNMG patientsMyasthenia gravisAChR-specific B cellsClinical needAcetylcholine receptor autoantibodiesSeronegative MG patientsSeronegative myasthenia gravisCell-based assaysAutoantibody positivityTrial eligibilityMG patientsReceptor autoantibodiesPatientsB cellsU.S. CentersNew treatmentsAssaysGravisAutoantibodiesSerostatusAChRPositivity
Academic Achievements & Community Involvement
Get In Touch
Contacts
Mailing Address
Yale University
300 George Street
NEW HAVEN, CT 06511
United States